"Our job now is to provide pharmacoeconomic data on the Polish market to the key Polish stakeholders, and in turn this will help in obtaining greater…
In Conversation
"We create a level playing field from an economic point of view, by offering competitive salaries and low taxes, coupled with the Polish low cost of…
"We are now looking to expand our impact into more markets, namely the Netherlands, Latvia, Lithuania, Germany, the UK and France."
"It is imperative that we find a balance between our own Angelini treatments and licensed products, as they are driving our turnover growth."
"We are absolutely concentrated in the private sector as the public sector in Poland does not historically partner with consultancy firms."
"Poland finds itself in a unique position, and we believe we have the chance to be considered as a hub for cardiovascular activity."
"In Europe, our business model is focused on classical brands and targeted promotion to specialists; a good example having the thrombosis business as one our specialist…
"Poland is the second largest country globally for AstraZeneca in regard to patient numbers and we are the leader in Poland, a very exciting time for…
"We built on our responsibility to explain to key stakeholders the benefits of considering the long-term perspective of healthcare, and in this regard, we have been…
"In the healthcare market, Poland is safe to invest, no matter the regulations."
"We see a very positive future in R&D and biotechnology for Poland, and the current government has put forward a highly ambitious plan to grow these…
"Poland is increasing in importance for AbbVie’s global clinical trials operations and the affiliate will continue to grow moving forward."
